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Abstract Currently available β-cell replacement thera-
pies for patients with diabetes, including islet and
pancreas transplantation, are largely successful in restor-
ing normal glucose metabolism, but the scarcity of organ
donors restricts their more widespread use. To solve this
supply problem, several different strategies for achieving
β-cell mass restoration are being pursued. These include
the generation of β cells from stem cells and their
subsequent transplantation, or regeneration-type approaches,
such as stimulating endogenous regenerative mechanisms
or inducing reprogramming of non-β cells into β cells.
Because these strategies would ultimately generate
allogeneic or syngeneic β cells in humans, the control
of alloimmunity and/or autoimmunity in addition to
replacing lost β cells will be of utmost importance. We
briefly review the recent literature on these three
promising strategies toward β-cell replacement or resto-
ration and point out the major issues impacting their
translation to treating human diabetes.
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Introduction
Progress in diabetes care over the last decade, such as the
routine use of recombinant insulins, continuous subcutane-
ous insulin infusions, and continuous glucose monitoring,
has improved and lengthened the lives of millions of
patients. As patients live longer they are more likely to
develop impaired awareness of hypoglycemia. Adrenergic
responses to hypoglycemia in patients with long-standing
diabetes are often severely blunted and nonspecific neuro-
glycopenic symptoms tend to predominate. As a result,
frequent, unanticipated hypoglycemic episodes continue to
plague patients. And, although it is well documented that
tight glycemic control helps delay or prevent end-organ
complications such as retinopathy and nephropathy, it is
also clear that the chief barrier to excellent glycemic control
is the constant fear of dangerous hypoglycemia.
Ideal control, without glycemic excursions or risk of
hypoglycemia, can only be achieved with physiologic β-
cell replacement, such as in the form of pancreas
transplantation or islet transplantation. One of the major
limitations to clinical islet or vascularized pancreas
transplantation, however, is the inadequate supply of
human cadaver donors. With over 30,000 patients
diagnosed with type 1 diabetes each year in the United
States and only about 8000 human cadaver donors, the
shortfall is obvious (http://www.jdrf.org/ and http://optn.
transplant.hrsa.gov/). Therefore, a reliable and clinically
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diabetes is desperately needed.
Alternative Sources of β Cells
Potential strategies for β-cell replacement can generally be
categorized as ex vivo strategies involving the generation of
β cells in vitro and their subsequent transplantation, or in
vivo regeneration-type approaches. In the former, it is
envisioned that cells would be isolated, derived, or grown
from other sources and subsequently transplanted either as
cells alone or encapsulated cells or cells together with
matrices as part of a tissue construct into the diabetic
recipient. Examples of this type of strategy might include
the differentiation of human pluripotent stem cells through
stereotypical developmental stages into pancreatic and
endocrine progenitor cells and ultimately into glucose-
responsive insulin-secreting β cells followed by transplan-
tation. Alternatively, β cells could be grown from other cell
types isolated directly from patients such as blood cells,
acinar cells, ductal cells, or liver cells, etc. Advantages of
the ex vivo strategy is that cells can be characterized,
quantified, and safety tested prior to transplantation.
Another strategy involves direct in vivo manipulations to
promote β-cell regeneration. One approach to achieve this
goal that has been explored recently is to reprogram other
somatic or parenchymal cells into becoming β cells by
overexpressing multiple key pancreatic transcription fac-
tors. Although this has been achieved in mice in vivo, it
may also be worthwhile to explore ex vivo conversion of
other pancreatic cell types to β cells, such as targeting
putative facultative progenitor cells to induce their conver-
sion into β cells.
Regardless of which strategy is pursued, it is generally
accepted that in order to be effective in human patients it
will be necessary to consider control of alloimmunity
and/or autoimmunity in conjunction with replacing lost β
cells. The next sections review in more detail three-
aforementioned promising strategies toward β-cell replace-
ment or restoration that are currently in preclinical studies:
derivation of insulin-producing cells from pluripotent stem
cells, reprogramming non-β cells into β cells, and methods of
promoting endogenous regeneration.
Pluripotent Stem Cells
The quest for alternative sources of β cells has catalyzed an
effervescence of studies aimed at translating known
molecular pathways of pancreas organogenesis into proto-
cols of stem cell differentiation in vitro. The prospect of
turning human stem cells, either embryonic (ES) or induced
pluripotent (iPS), into enough β cells to treat many patients
first derives merit from the renewal potential of stem cells,
whose populations can be amplified to clinically significant
levels and can serve as transplantation material. Second,
stem cell pluripotency implies that, under the action of the
appropriate inductive networks of growth factors, these
cells may give rise to any cell type, including fully
functional pancreatic endocrine lineages with therapeutic
potential in insulin-dependent diabetes. Third, the recent
advances in reprogramming human somatic cells to become
iPS cells [1–3] potentially allow the in vitro derivation of
an autologous therapeutic cell population.
Significant progress has been achieved over the last
decade in our ability to identify definitive endoderm and
pancreatic lineages in stem cell cultures and to directly
induce the differentiation of these cell types from human
pluripotent stem cells by sequentially recapitulating the
major stages in pancreas development. However, the
remaining challenge is to match the phenotypic profile of
expressed markers and transcription factors with functional
qualities such as glucose responsiveness and physiologic
insulin secretion in vitro, and, more importantly, in vivo.
Early reports of generating human pancreatic endoderm,
capable of differentiating in vivo into more mature islet cell
types secreting C-peptide, insulin, glucagon, or somatostat-
in in response to glucose stimulation [4–7] have been
followed by recent failed attempts to generate clinically
relevant levels of human endocrine hormone secretion
[8￿, 9], casting a shadow of doubt over the reproducibility
and efficiency of current protocols of β-like cell differen-
tiation from human pluripotent stem cells.
The past 3 years have brought to light several analogous,
yet surprisingly diverse, pancreatic lineage differentiation
protocols for human pluripotent stem cells focused on
deepening the exploration and applicability of signaling
pathways from embryonic pancreas development (summa-
rized in Table 1 and recently reviewed in [10]). Special
interest in recent reports has been dedicated to the role of
retinoic acid in converting definitive endoderm into
pancreatic duodenal homeobox-1 (Pdx1)-positive precur-
sors [11, 12], which were substantially increased in number
in the presence of antagonists to bone morphogenetic
protein (BMP) and hedgehog [9], epidermal growth factor
(EGF) [12], and low-density culture [13]. Additional
interest has been focused on fibroblast growth factors
(FGFs) in the fine modulation of endoderm differentiation
fates. A positive effect of FGF2 in conjunction with BMP4
and Activin A on endoderm differentiation was recently
reported by several groups [14￿, 15–18]. Xu et al. [17, 18]
also identified the role of combined FGF2/transforming
growth factor-β (TGF-β)/Activin A/BMP4 signaling in
endoderm differentiation and FGF2 signaling during later
stage patterning of the gut tube, leading to efficient
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PDX1-positive population capable of further differentiating
into some C-peptide-positive cells. Other recent reports
confirm that during the patterning stage optimal levels of
FGF2 [19] and FGF4 [11] correlate with improved foregut
specification to pancreatic lineage while inhibiting hepato-
cyte differentiation, however with more modest outcomes.
Whereas many protocols use FGF10 during pancreatic
precursor differentiation, a recent report validated on
multiple human embryonic stem (ES) cell lines associated
FGF10 and BMP signaling with hepatocyte differentiation,
and showed that inhibiting these factors strongly increases
pancreatic Pdx1-positive precursor differentiation achieving
50% to 80% enrichment [9]. The alternative use of FGF7 in
foregut endoderm differentiation from definitive endoderm
[12, 17] could thus prove to be a solution to circumvent
FGF10-driven hepatic lineage specification. Although
several recent human stem cell differentiation protocols
demonstrated robust endoderm differentiation and enriched
PDX1-positive cell populations, endocrine specification
was much more restricted and only a fraction of cells in
these studies express insulin or C-peptide. V ery few studies
were able to report physiologic levels of glucose-responsive
endocrine hormone secretion, and even fewer were able to
show efficient control of hyperglycemia after transplanta-
tion into diabetic mice [6, 8￿, 20].
A second approach to protocol optimization is based on
high-throughput screening for active small molecules and
agonists that mimic protein-based signaling pathways
during embryonic development. Treatment with histone
deacetylase inhibitors such as IDE1 and IDE2 resulted in
57% to 62% Sox17-positive definitive endoderm differen-
tiation [21], which was reportedly almost as efficient as
Activin A. High-content chemical screening identified
indolactam V’s ability to efficiently induce up to 46%
Pdx1-positive pancreatic progenitors from definitive endo-
derm cultures [22], which prompted inclusion of this
compound in other differentiation protocols [23]. Screening
for compounds that are active in later stages identified two
kinase inhibitors ALK-i I and ALK-i II, which guided the
differentiation of pancreatic progenitors to functionally
mature endocrine glucose-responsive α cells [15]. Notably,
Table 1 Overview of the most recent studies on pluripotent stem cell differentiation to endoderm and pancreatic lineage cells
Reference Source End point Key factors Functional Transplantation in animal models
Definitive Endoderm
Borowiak et al. [21] ES 57% to 62% Sox17+ IDE1, IDE2, screening N/A Cells integrate into developing
gut tube
Wang et al. [58] ES, iPS 73% Sox17+, 39%
primitive gut endoderm
CD49e
+, CD141
+,
CD238
+ sorting
N/A Cells differentiate to endodermal
progeny
Foregut Endoderm
Chen et al. [22] ES 45.8% Pdx1+ ILV , screening N/A Cells differentiate to pancreatic
progenitors
Johannesson et al. [11] ES 32% Pdx1+ FGF4, RA N/A N/A
Ameri et al. [19] ES 18% to 20% Pdx1+ FGF2 N/A N/A
Mfopou et al. [9] ES 50% to 80% Pdx1+ Noggin, RA; inhibition
of FGF10, BMP
N/A N/A
Endocrine Specification
Maehr et al. [50] iPS Mature-like C-peptide–
producing cells
T1D cell donors In vitro, glucose-responsive
C-peptide release
N/A
Mao et al. [20] ES Immature insulin-producing
cells
PLGA scaffolds
transplantation
In vitro and in vivo low
insulin release
In diabetic mice, decreased
fasting blood glucose
Zhang et al. [12] ES, iPS 25% mature-like insulin- and
C-peptide-producing cells
EGF, RA, Noggin, FGF7 In vitro, glucose-responsive
C-peptide release
N/A
Matveyenko et al. [8￿] ES 0.8% insulin- and C-peptide–
producing cells
Novocell protocol
reproducibility
In vivo low insulin and
C-peptide release
50% of implants develop into
islet-like structures
Cai et al. [13] ES 72% Pdx1+; endo- and
exocrine precursors
Low cell density, RA N/A N/A
Nostro et al. [14￿] ES, iPS Up to 25% C-peptide+,
immature endocrine
TGF-β inhibition; Wnt N/A N/A
Rezania et al. [15] ES Immature and mature-like
glucagon-producing cells
ALK inhibitors screening In vitro and in vivo glucagon release In normoglycemic and diabetic
mice, decreased glucagon
secretion
Thatava et al. [23] iPS Immature and mature-like
endocrine cells
ILV , GLP-1, In vitro C-peptide release N/A
Xu et al. [17] ES, iPS Up to 10% C-peptide–
producing cells
Activin, BMP , FGF2 In vitro C-peptide release N/A
BMP bone morphogenetic protein; EGF epidermal growth factor; ES embryonic stem cells; FGF fibroblast growth factor; GLP-1 glucagon-like
peptide-1; ILV indolactam V; iPS induced pluripotent stem cells; N/A study not available; pdx1 pancreatic duodenal homeobox-1; PLGA
polylactic-co-glycolic acid; RA retinoic acid; TGF-β transforming growth factor-β; T1D type 1 diabetes
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validated in vivo by following the differentiated cell
progeny after transplantation.
Despite the multitude of differentiation protocols cur-
rently described in the literature, current limitations in the
ability to generate fully functional β cells from human
pluripotent stem cells in vitro call for the need to refine the
existing protocols, by fine-tuning discrete or reciprocal
regulatory mechanisms involved in creating appropriate
temporal and spatial differentiation microenvironments in
culture. In support of this requirement, elegant studies on
mouse development recently showed that the timing and
duration of growth factor inductive networks, such as
mesodermal BMP and TGF-β signaling, are controlled
over very short time frames, in the range of hours, to insure
correct cell type specification in the foregut endoderm [24].
Moreover, spatial intra-endodermal cell interactions were
shown to be critical for the induction of pancreatic β cells
versus non-endocrine pancreas or intestine from adjacent
endoderm areas [25]. Furthermore, we know little about the
molecular events regulating islet formation and β-cell
functional maturation, which typically occurs in the late
gestational and early postnatal period. Therefore, we
anticipate that future pluripotent stem cell differentiation
studies will increase in complexity and that the aim will
shift from replicating limited arrays of gene expression
profiles of intermediate progeny, to generating fully
functional glucose-responsive pancreatic endocrine cells
capable of reliably restoring euglycemia in experimental
diabetes models.
Endogenous Regenerative Capacity of the Pancreas
The loss of β cells observed in type 1 diabetes mellitus has
stimulated great interest in the body’s endogenous capacity
to regenerate new β cells. Possible regenerative mecha-
nisms include proliferation and/or differentiation from
progenitors. β Cells have been shown in numerous studies
to replicate after birth in response to pancreatic injury or
disease, as well as under certain physiologic conditions
such as pregnancy. There is also some evidence to suggest
that adult stem cells or other progenitors may give rise to
new β cells in the postnatal and adult pancreas (i.e.,
neogenesis), but this possibility remains controversial, as
different laboratories have published conflicting results.
Here, we review recent studies, primarily in rodent models,
aimed at elucidating the mechanisms and capacity for β-
cell regeneration, including evidence for and against adult
neogenesis.
Early support for neogenesis arose from immunohisto-
chemical observations, such as the presence of budding
insulin-positive cells in the pancreatic duct epithelium
following partial pancreatectomy [26, 27]. However, using
a pulse-chase system to label the progeny of pre-existing β
cells, Dor et al. [28] provided evidence that all or nearly all
new β cells in the adult pancreas—including those
generated after pancreatectomy—are derived by replication
of pre-existing β cells. Although this finding generated
skepticism over the existence of neogenesis, the lineage-
tracing approach that was used labeled only β cell–derived
β cells, and did not have 100% efficiency, making it
impossible to completely rule out the possibility that some
β cells arose from other cell types.
In a subsequent study, Nir et al. [29] used a transgenic
mouse model to conditionally and selectively induce β-cell
death via doxycycline-dependent expression of diphtheria
toxin. In addition to conferring cell-type specificity, this
strategy also provided exquisite temporal control over both
the onset and the duration of β-cell ablation, and eliminates
some confounding experimental variables associated with
pancreatectomy, such as inflammatory responses. Using this
approach in combination with their lineage tracing system,
Nir et al. [29] confirmed that most or all regeneration
following loss of β cells in mice occurs via replication.
Moreover, they found that commonly used immunosup-
pressants inhibited endogenous regeneration rates by about
80%, suggesting that alternative immunosuppressive strat-
egies may improve outcomes for patients undergoing
pancreas or islet transplantation by permitting more active
endogenous replenishment mechanisms.
Whereas these studies focused on the pancreatectomy
model, other important studies were evaluating the mech-
anisms responsible for rodent regeneration after pancreatic
duct ligation. In 2008, Inada et al. [30] used a cell-lineage
tracing approach to determine whether ductal progenitors
can give rise to β cells after duct ligation in the adult
pancreas. The authors of this study developed a transgenic
mouse line in which the progeny of carbonic anhydrase II-
positive ductal cells expressed β-galactosidase (β-gal).
Following ductal ligation, in which islets distal to the
ligation site are destroyed while proximal islets are spared,
about 40% of β cells in the distal islets and about 12% in
the nonligated islets expressed β-gal, versus about 5% of β
cells expressing (endogenous) β-gal in wild-type animals.
Together, these results suggest that carbonic anhydrase II-
positive ductal cells can give rise to β cells following injury
in the adult pancreas.
The potential for neogenesis in the adult pancreas after
duct ligation is also supported by results from Xu et al.
[31], who mapped the fate of pancreas-specific progenitor
cells expressing the transcription factor neurogenin 3
(Ngn3) in adult mice following ductal ligation [31]. The
authors demonstrated that Ngn3-positive progenitors can
differentiate into β cells in vitro, albeit an embryonic
pancreas environment.
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that support the potential for adult neogenesis, the possi-
bility that pancreatic progenitors give rise to β cells in the
adult pancreas remains highly contentious. For example, a
study by Lee et al. [32] seems to run counter to the result
demonstrated by Xu et al. [31] Using Ngn3-GFP mice, Lee
et al. [32] showed that Ngn3 is not reactivated after
pancreatectomy demonstrating that Ngn3, whose expression
is transiently required during pancreas development, is not
required for regeneration following pancreatectomy even
though substantial pancreas regrowth occurred [32]. Other
studies by Teta et al. [33] using a sequential pulse of DNA
analogues, which incorporate into dividing cells, also seem
to support the concept that new murine β cells arise by
replication, rather than from tissue-specific progenitor cells,
during normal turnover, after pancreatectomy, or other
stimuli. Their results in the pancreas were strengthened by
the opposite finding in the intestine and hair follicle, tissues
in which endogenous progenitors are well characterized [33].
Using in vivo lineage tracing strategies, investigators
indelibly labeled progenitor cells expressing hepatocyte
nuclear factor 1β (Hnf1β), Muc1, or Sox9 and asked
whether these cells, which give rise to β cells during
normal development, can give rise to β cells after
pancreatic injury in the adult mouse. Collectively, these
studies suggest that regardless of cell type, differing
mechanisms exist for the origin of β cells during
embryogenesis versus adult life. For example, in a study
published in 2009, Solar et al. [34] traced the fate of
pancreatic progenitor cells expressing the early pancreatic
transcription factor Hnf1β. The authors found that in the
embryonic mouse, Hnf1β-positive progenitor cells primar-
ily give rise to ductal cells, but can also assume an acinar or
endocrine fate (including β cells) if labeled early in
development. In the adult, however, Hnf1β-positive cells
assumed a strictly ductal fate, even after ductal ligation or
alloxan-induced β-cell ablation, followed by treatment with
the neogenesis-promoting factors EGF and gastrin. Two
more recent studies have supported the findings of Solar et
al. [34]. Kopinke and Murtaugh [35] followed the fate of
cells expressing the exocrine pancreatic marker, Muc1, and
found that these cells can give rise to endocrine cell types
during embryogenesis but not after birth. Similarly, Kopp et
al. [36] followed the fate of cells expressing Sox9, which
are found at the interface of small ducts and acini and had
previously been shown to be capable of assuming an
endocrine fate when injected into fetal pancreatic explants
[37]. The authors found that Sox9-positive cells were
multipotent before birth, giving rise to all types of
pancreatic cells. However, in the adult, Sox9 cells failed
to generate endocrine cells under basal conditions or after
ductal ligation, although ligation did lead to the presence of
Ngn3 expression in Sox9-positive cells [36].
A study from Thorel et al. [38￿] revitalizes the concept
of adult β-cell neogenesis. The authors induced diphtheria
toxin-mediated apoptosis selectively in β cells using a
transgenic mouse system similar to the one used by Nir et
al. [29]. However, in this study expression of the toxin
resulted in almost total ablation (> 99%) of β cells. Under
these conditions, regeneration of insulin-secreting cells
occurred not via β-cell replication but primarily through
transdifferentiation of pre-existing α cells. Interestingly, the
resulting insulin-positive cells were also glucagon-positive,
indicating that they retained at least some fundamental
aspects of α-cell identity. Although the physiologic
characteristics of these “hybrid” cells remain unexplored,
they may prove useful in harnessing the endogenous
regenerative capacity of the pancreas to achieve thera-
peutic outcomes.
As this survey of recent studies illustrates, the cellular
origins of new β cells in the adult pancreas remain highly
contentious. When comparing the results of these studies, it
is important to consider how each study differs from the
others. For example, different experimental models of
pancreatic injury produce different percentages of β-cell
ablation, may trigger apoptotic or necrotic cell death, and
may or may not be accompanied by inflammatory
responses. Furthermore, each study was specifically
designed to test whether β cells can arise from a particular
cell type of interest. The key methods and findings of each
of these studies are summarized in Table 2.
Finally, it must be noted that most of what is known
about β-cell regeneration, including all of the studies
described above, comes from rodent models. Because of
the inherent difficulty of studying in human subjects, little
is known about turnover of β cells over the human life
span. In a recent study, Perl et al. [39] showed that β-cell
turnover primarily occurs in the first three decades of
human life. The authors analyzed iododeoxyuridine/bromo-
deoxyuridine expression in pancreas tissue from 10
deceased patients who had previously received thymidine
analogues as part of a cancer-related clinical trial. Cells co-
labeled with analogues and insulin were only observed in
patients younger than 30 years old. The authors further
confirmed this finding using a recently developed DNA
carbon-dating technique [40] on tissue from three cadaver
donors. Thus, although these findings are based on a
relatively small sample sizes, it would appear that the
capacity for β-cell generation is extremely limited in the
adult human pancreas. However, the replicative power of β
cells may be revealed during conditions such as pregnancy
[41] or autoimmune disease [42]. The relatively low β-cell
proliferation rate under basal conditions and significantly
higher replication rate under provocative conditions indi-
cates that β-cell mass is tightly regulated, yet there is
substantial potential for expansion of existing β cells.
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Methods for de- and transdifferentiation of mature cell
types, or now more commonly called cellular reprogram-
ming, are likely to contribute to the future of regenerative
medicine because they could facilitate restoration of cellular
functions lost in disease states. In the case of diabetes, a
primary focus has been on reprogramming different cell
types to become glucose-responsive, insulin-secreting β-
like cells.
There has been long-standing interest in the possibility
of transforming hepatocytes into β cells. Liver and
pancreas tissues share a common endodermal origin and
hepatocytes, like β cells, express glucose transporter 2
(GLUT-2) and glucokinase, two key proteins involved in
stimulus secretion coupling in the β cell. However, it is
well known that hepatocytes lack several important com-
ponents of insulin secretion, such as enzymes that convert
proinsulin to insulin. In one study, adenovirus-mediated
gene transfer of the transcription factor Pdx1 into mice was
used to reprogram 60% of hepatocytes [43]. The authors
detected increased quantities of insulin and proinsulin in the
liver and were able to show decreased blood-glucose levels
in animals with diabetes induced by streptozotocin. Subse-
quently, another study from Wang et al. [44] tried to use
adeno-associated virus (AA V) instead of adenovirus to
reprogram liver cells. Interestingly, the authors of this study
found that AA V-mediated transfer of β-cell markers Pdx1 or
Ngn3 alone failed to reduce symptoms of diabetes, but
when it was coadministered with an irrelevant adenoviral
vector the treatment corrected hyperglycemia and weight
loss, increased blood insulin levels, and improved glucose
tolerance in diabetic mice. The authors suggested that the
immune response against adenovirus is required for
reprogramming of hepatocytes into a β-like cell fate.
Several other transcription factors important for β-cell
differentiation have also been introduced into the liver. For
example, Kaneto et al. [45] showed that adenovirus transfec-
tion of MafA, Pdx1, and NeuroD induced production of
insulin from hepatocytes and helped control blood-glucose
levels in diabetic animals. Sapir et al. [46]r e p r o g r a m m e d
cells from human liver biopsies using adenovirus-mediated
transfer of Pdx1. The reprogrammed cells secreted C-peptide
and expressed GLUT-2 as well as several important
transcription factors present in mature β cells, such as
Nkx2.2, Nkx6.1, and Pax4. The cells also expressed the
neuroendocrine vesicular markers SCG-2 and SGNE1, as
well as prohormone convertase 2. After these cells were
transplanted into streptozotocin-induced diabetic mice, the
animals exhibited decreased blood-glucose levels compared
with animals that received non-transformed human liver
cells. Although these results are promising, it remains
unclear whether the cells maintain the β-like phenotype for
a long period of time, especially if transplanted into the liver
where they could conceivably revert to a hepatocyte identity.
Focusingonanabundant, nonendocrinepancreascelltype,
Zhouetal.[47￿] convertedexocrinecellsofimmune-deficient
mice into insulin-secreting cells though viral-mediated gene
transfer of the transcription factors Ngn3, MafA, and Pdx1.
Thistransformationpartlyreducedthe elevatedblood-glucose
concentration observed following ablation of pre-existing β
cells with streptozotocin, but failed to fully normalize
glycemia. The lack of full rescue may have been due to
insufficientnumbersofnewinsulin-secretingcells,ortoalack
of organized islet structures that could respond properly to
glucose stimuli. Nonetheless, the transformation of cells
Table 2 Some recent murine models studying mechanisms of endogenous β-cell regeneration in the adult pancreas
Reference Ablation method Cell type traced Supports
adult
neogenesis?
Dor et al. [28] Partial pancreatectomy (70%) Existing β cells No
Teta et al. [33] Partial pancreatectomy Not specific, replicating cells No
Nir et al. [29] DTX ablation of β cells (~ 80%) Existing β cells No
Inada et al. [30] Ductal ligation Carbonic anhydrase II+ differentiated ductal cells Y es
Xu et al. [31] Ductal ligation Ngn3+ progenitor cells Y es
a
Solar et al. [34] Ductal ligation, alloxan-induced di-
abetes
Hnf1β+ progenitor and ductal cells No
Thorel et al. [38￿] DTX ablation of β cells (> 99%) α cells Y es
Kopinke and Murtaugh
[35]
– Muc1+ progenitor and adult ductal and acinar cells No
Kopp et al. [36] Ductal ligation Sox9+ progenitor and ductal cells including duct/
centroacinar cells
No
aNgn3+ cells became β cells in an embryonic pancreas environment
DTX diphtheria toxin; Hnf1β hepatocyte nuclear factor 1β; Ngn3 neurogenin 3
Curr Diab Rep (2011) 11:392–401 397already present in the adult pancreas to assume a β-like
function is an important and promising advance.
In another important study illustrating cellular reprog-
ramming to β cells, Collombat et al. [48] used a Cre/lox
transgenic mouse system to selectively drive ectopic
expression of Pax4 in cells that expressed either Pdx1
(pancreatic progenitor cells), Pax6 (endocrine progenitor
cells), or glucagon (α cells) in postnatal adult mice.
Expression of Pax4 in each of these cell types increased
the number of insulin-positive cells present in the pancreas
at the expense of other endocrine cell types. Pax4
expression also restored normoglycemia in younger (≤
4 weeks old) mice following ablation of β cells with
streptozotocin, and 41% of these animals lived for 2 months.
However, older (> 4 weeks old) animals died spontaneously
and showed signs of hyperglycemia, in spite of also having
increased insulin-positive cell counts. Furthermore, all older
animals expressing ectopic Pax4 died following treatment
with streptozotocin, indicating an age-restricted effect. It is
unclear whether insulin-positive cells generated by ectopic
Pax4 expression are nonfunctional in the older animals, or
whether these animals have become insensitive to insulin.
Nonetheless, this study provides important evidence that α
cells may be a useful progenitor population from which
insulin-producing cells could be derived. Future investiga-
tions may be directed toward achieving direct cellular
reprogramming without introduction of exogenous genes
and/or by specifically altering chromatin states.
Although considerable progress has been made in
reprogramming cells toward a β-like state, there remains
no proven method for generating a continual source of
glucose-responsive, insulin-secreting β cells with long-term
stability suitable for the treatment of diabetes. Future
challenges will include not only establishing such a source,
but also making it safe for the treatment of human patients.
Nevertheless, the possibility of acquiring cells from a
patient’s own body, transforming them into a stable line of
glucose-responsive, insulin-secreting β-like cells, and sur-
gically reintroducing them would likely revolutionize the
treatment of diabetes.
Translational Considerations
To fulfill their therapeutic potential, alternative sources of β
cells must meet a challenging set of requirements, such as
functional maturation to clinically relevant numbers of
endocrine cells, and persistent engraftment and survival, but
also must satisfy safety concerns related to tumorigenicity,
genetic stability, adventitious pathogens, containment, host
tissue toxicity, and dosage.
To begin with, solid evidence that human pancreatic
precursors can mature functionally in vitro or in vivo and
cure experimental diabetes in animal models is absolutely
necessary, yet is currently still missing. In addition to
differentiating into functional endocrine cells for the duration
of experimental assays, ideally pancreatic precursors must
also be capable of engrafting and surviving in vivo for
extended periods of time. To this end, innovative solutions,
such as controlling the size of precursor clusters by covalent
microcontact printing of laminin on cell culture substrates
[49], show promise to allow the efficient production of
human uniform-size islet-like structures with optimized
nutrient and oxygen access after engraftment in vivo.
An additional challenge to the in vivo survival of
pancreatic precursors in human patients is the susceptibility
ofβcells toinflammation-inducedcelldeathandthepresence
of autoimmune and alloimmune responses that may compro-
mise an otherwise functional transplant. In this respect, the
breakthrough of generating iPS cells from human tissue [1, 2]
and differentiating them to pancreatic cell types [12, 14￿, 18,
23, 50, 51] that potentially may be transplanted back to the
patient from whom the iPS cells were derived for β-cell
replacement holds a significant therapeutic promise for
circumventing allogeneic immune responses that ES-
derived precursors might otherwise elicit. A proof of concept
of using iPS cell progeny in curing diabetes has been
recently reported in a mouse system. Alipio et al. [52]
derived iPS cells from murine skin fibroblasts and differen-
tiated them into insulin-secreting β-like cells in vitro that
responded to glucose stimulation under physiologic or
pathologic conditions. These insulin-secreting β-like cells
were transplanted via intraportal vein injection into the livers
of two different mice lines modeling type 1 and type 2
diabetes. Although cells engrafted and subsequently cor-
rected hyperglycemia in both models, the insulin-deficient
model that was used was not an autoimmune model. In fact,
studies testing the efficacy of syngeneic iPS cells in
autoimmune diabetes models in vivo or alternatively testing
the susceptibility of type 1 diabetic human iPS cells to
autoimmune destruction in vitro have yet to be reported.
Nonetheless, whether iPS cell-derived β cells would be
destroyed upon transplantation into subjects with type 1
diabetes is an important clinical issue as some past human
experiments might predict [53]. In these cases, pancreatic
grafts from a nondiabetic twin were transplanted into the
diabetic twin without immunosuppression. Pathologic eval-
uation of these pancreas transplants, which failed early post-
transplant, exhibited classic insulitis and patients reverted to
hyperglycemia, whereas nonpancreatic grafts would normal-
ly be accepted between these twin siblings. A similar
pancreas transplant that was subsequently performed with
low-dose immunosuppression succeeded long term [54].
Based on these data, the possibility exists that destruction of
any autologous β-cell population, be it derived from iPS
cells in vitro, induced by reprogramming, or by endogenous
398 Curr Diab Rep (2011) 11:392–401regeneration, when placed in an autoimmune environment,
may occur and will thus need to be formally tested.
With the rapid advance of preclinical research on new
sources of β cells for cell-replacement therapies, a number of
safety and good manufacturing practice issues begin to arise.
For instance, one of the principal unique aspects of using ES
or iPS cells as alternative sources of β cells is the need to
thwart the teratogenic potential that transplantation of non-
purified stem cell–derived populations might hold. Moreover,
recent studies on numerous human iPS cell lines reprog-
rammed using a variety ofmethods showed thatiPS cells may
harbor protein-coding point mutations, which could have
arisen in the original donor tissue or resulted from reprogram-
ming [55, 56]a sw e l la sa na s s o r t m e n to fe p i g e n e t i cm a r k
abnormalities [57], all adding to a possible increase in their
tumorigenic potential. One prospective solution to these
challenges is the sorting of target precursors from heteroge-
neous populations based on surface molecules associated
with differentiation. Newly described CD141 and CD238
surface markers allowed for higher efficiency of human
definitive endoderm generation by cell enrichment [58]a n d
similarly, selection of CD326- (i.e., epithelial cell adhesion
molecule) [59]o rC D 2 4[ 60]-expressing cells resulted in
higher yields of pancreatic endoderm cells, while signifi-
cantly diminishing the teratogenic/tumorigenic cell numbers
allowing for safer transplantation [58, 59]. As an alternative,
bioengineering innovations such as encapsulation devices
that permit molecular diffusion while preventing precursor
cell escape or immune cell penetration are currently being
considered [61].
A new level of translational complexity is introduced by
reprogramming protocols. In addition to future efficacy and
scalability tests that would need to be done in humans,
safety concerns arise related to various gene delivery
systems. Primary among these concerns is the issue of
random integration and potential for mutagenesis. Bystander
effects and toxicities of vectors and viral delivery
systems are likewise critical issues. Even though a
cellular reprogramming clinical trial would likely be
approached with caution, such an approach holds
significant potential to materialize into relevant therapies
while nongenetic means of reprogramming are actively
being investigated. Altogether, there is significant evidence in
recent literature surveys that innovative resources and
sophisticated new methodologies are actively being applied
toaddressmanyofthechallengesthattranslationalintegration
of alternative β-cells sources currently face.
Conclusions
Society’s ability to ultimately confront the dramatic
increase in diabetes prevalence worldwide and the
limitations of existing therapeutic options will largely
depend on the aggressiveness to which research pursues
developing alternative sources of β cells. Whether new
β cells are derived from human pluripotent stem cells in
vitro and transplanted, or generated in vivo by either
reprogramming adult cells or regenerating precursors,
these therapies offer tremendous advantage over islet or
pancreas transplantation by virtue of their renewal
potential, ample supply, syngeneic source, ability to be
quality control tested, and capacity for cell number
control through homeostatic regulation. With these
beneficial attributes comes the need to control the
outcome of their differentiation to achieve the desired
functional endocrine maturity in addition to finding
ways to overcome autoimmunity. Collaborative multidis-
ciplinary research bringing together the fields of
autoimmunity, tolerance, encapsulation, biomaterials,
stem cells, and developmental biology will undoubtedly
furnish future therapeutic opportunities.
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